CMS Seeks Input to Shed Light on Pharmacy Benefit Manager Practices

You might care about this because the government wants your help to understand how Pharmacy Benefit Managers, or PBMs, work. The Centers for Medicare & Medicaid Services, known as CMS, has issued a Request for Information, called an RFI. They are gathering details about PBM services and how PBMs get paid. This effort is directly linked to new laws that aim to change how PBMs operate starting in 2028. These new laws will restrict what PBMs and their related companies can receive for services for Medicare Part D drugs. The laws also add new data reporting rules. CMS needs this input to properly put these new rules into action. They are specifically asking about what counts as a PBM, what counts as a related company or "affiliate," and what is considered a "bona fide service fee." This RFI is an important step towards making drug pricing and PBM business practices more transparent for everyone, especially for Medicare Part D beneficiaries. This document is interesting because it signals a strong move by the government to bring transparency to an area that has often been unclear. PBMs play a large role in determining how much people pay for prescription drugs, especially those covered by Medicare Part D. Until now, much of how they make money and their business arrangements have been complex and hard to understand for many. The RFI asks very specific questions about the definitions of PBMs and their affiliates. It also asks about what a 'bona fide service fee' means in practice. These questions suggest CMS wants to define these terms clearly to enforce the new payment restrictions and reporting requirements. This could lead to big changes in how drug costs are managed and how pharmacies are paid. It affects drug pricing and access for millions of Americans. By asking for public input, CMS is trying to make sure the new rules are fair and effective for all involved parties. Many different groups of people will find this legal document very relevant. Pharmacy Benefit Managers and their affiliates will be directly impacted by any new regulations based on this input. Pharmacies, including retail, mail-order, and specialty pharmacies, should pay close attention because PBM practices directly affect their payments and operations. Drug manufacturers have a stake because PBMs negotiate drug prices and rebates. Insurance companies that offer Medicare Part D plans also need to follow this closely, as PBMs work for them. Patient advocacy groups and healthcare providers who care about drug affordability and access for patients will find this important. Lastly, any Medicare Part D beneficiary concerned about their prescription drug costs should be aware of these efforts. This RFI could shape the future of drug pricing and availability in the United States.